The cytosolic serine/threonine Raf kinases play a central role in evolutionary conserved signal transduction pathways. An impressive number of publications implicates these enzymes in a variety of biological processes, most prominently in regulated and deregulated proliferation. Because of this, they are considered attractive therapeutic targets. Gene ablation experiments have now revealed that in the context of the mouse embryo Raf-1 and B-Raf play essential anti-apoptotic roles that cannot be rescued by the other Raf isoforms. In the case of Raf-1 it is clear that its best-studied downstream target, the MEK/ERK pathway, does not mediate the anti-apoptotic function of the kinase. These experiments have shed new light on the biological role of the Raf kinases and have prompted a search for alternative substrates mediating it.
Activation of MEK/ERK: A family business
Raf is a family of three serine/threonine specific kinases (A-Raf, B-Raf, and Raf-1) ubiquitously expressed throughout embryonic development.1 All three enzymes can be activated by the small G protein Ras and relay upstream input signals to the MEK/ERK module. Activated ERK controls an impressive roster of substrates, ranging from metabolic enzymes to specific transcription factors whose phosphorylation affects the pattern of gene expression. Within this signaling cascade, Raf interacts physically with MEK-1 via its kinase domain and with GTP-loaded Ras via its N-terminus. The high affinity binding to activated Ras mediates the translocation of Raf-1 from the cytosol to the plasma membrane, where activation occurs via a complex, yet incompletely defined mechanism involving phosphorylation and dephosphorylation.2 Both Ras and Raf are proto-oncogenes, and deregulation of the ERK pathway is involved in the pathogenesis of severe diseases that affect large portions of the population. Specifically, the ERK pathway is deregulated in more than 30% of common cancers. Therefore, the Raf kinases are an attractive target for novel therapies aimed at interfering with its activation process and at eventually reversing its deregulated functions.
The three Raf isoforms differ in their ability to interact with Ras,3,4 to activate the MAPK pathway,5 and to transform NIH 3T3 cells.5 In all three cases, the ranking is B-Raf>>Raf-1>>A-Raf. A-raf, B-raf and c-raf-1-deficient mice have been generated. A-raf-deficient mice are born alive and show neurological and intestinal defects, depending on the genetic background.6 In contrast, B-raf and c-raf-1-deficient embryos both die around midgestation. The former succumb to vascular hemorrhage due to apoptotic death of differentiated endothelial cells.7 c-raf-1-deficient embryos show increased apoptosis of embryonic tissues8 or, more selectively, of the fetal liver,9 depending on the genetic background. These divergent phenotypes show that Raf isoforms serve distinct essential functions in different tissues and that they cannot always compensate for each other.
The genetic experiments described above have yielded two rather unexpected results:
The essentials: Raf kinases and apoptosis
These results are surprising given the overwhelming amount of published evidence indicating a role for Raf in cell cycle progression. However, the concept that Raf kinases play a prosurvival role is not entirely new. It has been put forward in a number of studies largely based on overexpression and, in some cases, forced mitochondrial localization of the constitutively active enzymes or of dominant negative, kinase-dead mutants.10,11,12,13,14,15,16,17,18,19,20 The matter of the mechanism(s) and substrate(s) involved in this prosurvival function is still entirely open.
The classical Raf effector module MEK/ERKs has been reported to antagonize apoptosis,18,21,22,23,24,25 and a role for these effectors has been proposed downstream of both B-Raf and Raf-1.15,18 In the case of B-Raf, apoptosis inhibition occurs downstream of cytochrome c release, suggesting that caspase inhibitors (IAPs26) might be the relevant targets.15 Indeed, sensory and motoneurons from B-Raf-deficient embryos in culture fail to express specific IAPs, and are unable to survive in response to neurotrophic factors.27
In contrast, a mitochondrial pool of Raf-1 molecules, which do not activate MEK, reportedly exert their prosurvival effects upstream of cytochrome c release by phosphorylating the pro-apoptotic Bcl-2 family member Bad.13,14,20,28,29 Phosphorylation of Bad results in its translocation to the cytosol and ultimately in the inhibition of cytochrome c release. Anti-apoptotic Bad phosphorylation, however, can be brought about by other kinases, e.g. by the MEK/ERK module30,31 but, most prominently, by the antiapoptotic kinase Akt/PKB.32 The relationship between Raf and Akt/PKB is presently unclear. Akt is able to phosphorylate Raf-1 on a negative regulatory residue, thereby reducing its activity toward the MEK/ERK module.33 This might be a way of re-directing Raf-1 activity towards other anti-apoptotic substrates. Consistent with this idea, mitochondrial Raf-1 has been recently proposed to mediate the prosurvival function of Akt in hematopoetic cells.13 On the other hand, Akt appears to mediate at least part of the prosurvival signal of oncogenic Raf.18
In addition to MEK/ERK and Bad, Raf-1 can regulate the anti-apoptotic transcription factor NF-κB,34 which has been shown to participate in the transcriptional regulation of IAPs35,36 as well as of c-FLIP, an inhibitor of caspase-8 activation.37 Raf-1 apparently induces NF-κB activation by a mechanism that does not involve MEK/ERK but rather another MAPKKK, MEKK-1, upstream of the IκB kinase complex.38
The last MEK/ERK-independent prosurvival function of Raf-1 reported consists in antagonizing the activity of apoptotic signal-regulated kinase (ASK1). ASK-1 plays an essential role in TNF-α and H2O2-induced apoptosis,39 while Raf-1 does not.9 Thus, ASK-1 inhibition is unlikely to be the basis of the essential anti-apoptotic function of Raf-1.
Intriguingly, the investigation of the anti-apoptotic pathways that have been connected to Raf-1 in the literature gave only negative results: activation of the MEK/ERK and NF-κB is normal in Raf-1-deficient macrophages and fibroblasts, and cytochrome c release is not increased. However, caspase activation by selected apoptotic stimuli is enhanced in cells and mice lacking Raf-140 (Piazzolla et al., unpublished observations). The apoptotic stimuli affected by the lack of Raf-1 include pathogen-induced apoptosis of macrophages,40 and, in fibroblasts, growth factor deprivation and Fas, but not TNF-α-mediated apoptosis.9 Thus, Raf-1 does not perform a general prosurvival function, but is rather involved in counteracting specific apoptotic pathways by restraining caspase activation.
Although several pieces of the puzzle are missing, the analysis of knock-out animals has unequivocally established the essential anti-apoptotic role of Raf-1 and B-Raf, and, at least in the case of Raf-1, has shown that this function is effected by targets distinct from the ones described in the literature. We can look forward to future studies employing conditional knockouts to ascertain whether the anti-apoptotic function of the Raf kinases is still essential in the context of adult animals, and in which tissues; and whether the kinases have an irreplaceable function in the establishment or progression of tumors. The combination of phenotype analysis with the biochemical investigations of their molecular basis in ablated cells will help defining the function(s) of Raf-1, B-Raf and their relevant biological targets. The information obtained will be instrumental in assessing the potential of these molecules as therapeutic targets and in directing the design and use of pharmacological kinase inhibitors.
References
Wojnowski L et al. 2000 Mech. Dev. 91: 97–104
Kolch W . 2000 Biochem. J. 351: 289–305
Marais R et al. 1997 J. Biol. Chem. 272: 4378–4383
Weber CK et al. 2000 Oncogene 19: 169–176
Pritchard CA et al. 1995 Mol. Cell. Biol. 15: 6430–6442
Pritchard CA et al. 1996 Curr. Biol. 6: 614–617
Wojnowski L et al. 1997 Nat. Genet. 16: 293–297
Huser M et al. 2001 EMBO J. 20: 1940–1951
Mikula M et al. 2001 EMBO J. 20: 1952–1962
Wang HG et al. 1994 Oncogene 9: 2751–2756
Weissinger EM et al. 1997 Mol. Cell. Biol. 17: 3229–3241
El-Ashry D et al. 1997 Oncogene 15: 423–435
Majewski M et al. 1999 Cancer Res. 59: 2815–2819
Salomoni P et al. 1998 J. Exp. Med. 187: 1995–2007
Erhardt P et al. 1999 Mol. Cell. Biol. 19: 5308–5315
Hoyle PE et al. 2000 Leukemia 14: 642–656
Arsura M et al. 2000 Mol. Cell. Biol. 20: 5381–5391
von Gise A et al. 2001 Mol. Cell. Biol. 21: 2324–2336
Lehmann K et al. 2000 Genes Dev. 14: 2610–2622
Peruzzi F et al. 2001 J. Biol. Chem. 276: 25990–25996
Deng X et al. 2000 Proc. Natl. Acad. Sci. USA 97: 1578–1583
Holmstrom TH et al. 2000 EMBO J. 19: 5418–5428
Aoudjit F, Vuori K . 2001 J. Cell. Biol. 152: 633–643
Le Gall M et al. 2000 Mol. Biol. Cell 11: 1103–1112
Tran SE et al. 2001 J. Biol. Chem. 276: 16484–16490
Deveraux Q L, Reed J C . 1999 Genes Dev. 13: 239–252
Wiese S et al. 2001 Nat. Neurosci. 4: 137–142
Wang HG et al. 1996 Cell 87: 629–638
Peruzzi F et al. 1999 Mol. Cell. Biol. 19: 7203–7215
Scheid M P, Duronio V . 1998 Proc. Natl. Acad. Sci. USA 95: 7439–7444
Scheid MP et al. 1999 J. Biol. Chem. 274: 31108–31113
Datta SR et al. 1999 Genes Dev. 13: 2905–2927
Zimmermann S, Moelling K . 1999 Science 286: 1741–1744
Foo SY, Nolan GP . 1999 Trends Genet. 15: 229–235
Wang CY et al. 1998 Science 281: 1680–1683
Stehlik C et al. 1998 J. Exp. Med. 188: 211–216
Micheau O et al. 2001 Mol. Cell. Biol. 21: 5299–5305
Baumann B et al. 2000 Proc. Natl. Acad. Sci. USA 97: 4615–4620
Tobiume K et al. 2001 EMBO Rep. 2: 222–228
Jesenberger V et al. 2001 J. Exp. Med. 193: 353–364
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baccarini, M. An old kinase on a new path: Raf and apoptosis. Cell Death Differ 9, 783–785 (2002). https://doi.org/10.1038/sj.cdd.4401070
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4401070
This article is cited by
-
Current advances in the application of proteomics in apoptosis research
Science China Life Sciences (2011)
-
Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a
Oncogene (2007)
-
Activation of the MAP Kinase Pathway Induces Apoptosis in the Merkel Cell Carcinoma Cell Line UISO
Journal of Investigative Dermatology (2007)
-
Prolonged activation of ERK1,2 induces FADD-independent caspase 8 activation and cell death
Apoptosis (2006)
-
Therapeutic targets in melanoma: MAPKinase pathway
Current Oncology Reports (2006)